Pmv Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
PMV Pharmaceuticals reported promising interim Phase 2 data for its lead oncology candidate, rezatapopt, securing Orphan Drug Designation and planning an FDA submission in Q1 2027, despite ongoing significant net losses.
NASDAQ
PMV Pharmaceuticals continues to focus on its lead drug candidate, rezatapopt, while managing costs through a restructuring plan.
NASDAQ
PMV Pharmaceuticals updates its executive compensation and severance policies, outlining benefits for officers upon termination under various circumstances.